047nok
0,7 %
Date:2026-01-05Time:11:51:55Latest report:Q2-2024List:Oslo BorsTicker:ONCIN
Market Cap:212 mnokEnterprise Value:146 mnokNet Sales:5,41 mnokEarnings:-107,6 mnokEmployees:0ISIN:NO0013251173

Ratios

10-year key figure history for Oncoinvent turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Oncoinvent with index and moving average MA50 and MA200.

Stockprice:0,47
MA50:0,75
MA200:1,25
Price/MA200:-62,3 %
RSI (14):38,7
Price/MA50:-37,5 %

Description

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Biotechnology